Pfizer (NYSE:PFE | PFE Price Prediction) trades at $25.62, pays a 6.7% dividend yield, and just posted five straight quarterly EPS beats before stumbling in Q1. Yet the stock is up only 6.37% YTD this ...

Pfizer is rated a Buy with 55%+ upside potential, driven by a robust pipeline and undervalued forward earnings. Read more on ...

Pfizer (NYSE:PFE) has quietly built momentum in 2026, with shares up 6.61% year-to-date and 2.70% over the past year. The stock is currently trading near $26.84 but remains well below its 52-week high ...

PFE trades above 50- and 200-day SMAs since January, rising about 12.8% in 2026 Pfizer's growth is driven by oncology strength, new products, and Seagen acquisition gains PFE faces weak 2026 guidance, ...

Wall Street analysts forecast that Pfizer (PFE) will report quarterly earnings of $0.66 per share in its upcoming release, pointing to a year-over-year decline of 37.7%. It is anticipated that ...

Stock index futures were higher on Tuesday as tech stocks continued to recover, with the SpaceX IPO set for Friday. Here are the four stocks to watch on the day: JetBlue (JBLU) rose 1.47% in premarket ...

Following its June 18, 2026 announcement of a Chief Financial Officer transition, Pfizer reaffirmed the full-year 2026 financial guidance it first issued on December 16, 2025 and reiterated on May 5, ...